|
ALKBH5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.26499999364427E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.18719964151637E-10 |
| Normal-vs-Stage2 |
1.798420E-01 |
| Normal-vs-Stage3 |
2.0796000477219E-09 |
| Normal-vs-Stage4 |
1.14679998830525E-09 |
| Stage1-vs-Stage2 |
5.343500E-03 |
| Stage1-vs-Stage3 |
3.361800E-01 |
| Stage1-vs-Stage4 |
9.903500E-02 |
| Stage2-vs-Stage3 |
1.961830E-03 |
| Stage2-vs-Stage4 |
4.983000E-04 |
| Stage3-vs-Stage4 |
4.151400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.83100267859527E-11 |
| Normal-vs-AfricanAmerican |
8.816000E-04 |
| Normal-vs-Asian |
2.97539999971619E-07 |
| Caucasian-vs-AfricanAmerican |
3.713000E-01 |
| Caucasian-vs-Asian |
9.513000E-01 |
| AfricanAmerican-vs-Asian |
4.174600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.39080000019598E-07 |
| Normal-vs-Female |
1.52120005481038E-09 |
| Male-vs-Female |
6.650600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.60449472889013E-11 |
| Normal-vs-Age(41-60Yrs) |
2.52900000052847E-07 |
| Normal-vs-Age(61-80Yrs) |
2.39589999995182E-06 |
| Normal-vs-Age(81-100Yrs) |
4.246100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.600400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.006830E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.399800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.714000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.074600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.942000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.79680000000193E-05 |
| Classical-VS-Follicular |
2.840700E-04 |
| Classical-VS-Other |
2.949400E-01 |
| Classical-VS-Normal |
1.69599889687788E-11 |
| Tall-VS-Follicular |
5.31169996875747E-09 |
| Tall-VS-Other |
4.258800E-01 |
| Tall-VS-Normal |
1.78723702504158E-12 |
| Follicular-VS-Other |
6.274100E-02 |
| Follicular-VS-Normal |
4.570000E-02 |
| Other-VS-Normal |
6.189400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.76413999999347E-05 |
| Normal-vs-N1 |
6.38045172252077E-13 |
| N0-vs-N1 |
4.27680000000263E-05 |
|
|
